{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:23:48Z","timestamp":1776180228368,"version":"3.50.1"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Interdisziplin\u00e4re Zusammenarbeit: Aktuell werden nur 25% aller\n      PMR-Patienten (PMR: Polymyalgia rheumatica) fach\u00e4rztlich-rheumatologisch \u00fcberwiesen. Eine\n      Expertenkommission empfahl k\u00fcrzlich die fach\u00e4rztliche Diagnosebest\u00e4tigung. Dadurch k\u00f6nnen\n      Fehldiagnosen und Krankenhausaufenthalte vermieden sowie niedrigere Glukokortikoiddosen\n      erreicht werden.<\/jats:p><jats:p>\n            Bildgebende Untersuchungen: Mithilfe der Sonografie, MRT oder\n      PET-CT lassen sich typische periartikul\u00e4re entz\u00fcndliche Ver\u00e4nderungen finden, insbesondere im\n      Schulter- und Beckeng\u00fcrtelbereich, wobei f\u00fcr den klinischen Alltag die Sonografie meist\n      ausreichend ist.<\/jats:p><jats:p>\n            Riesenzellarteriitis (RZA) bei PMR: Bei 20\u201325% aller neu\n      diagnostizierten PMR-Patienten ohne RZA-Symptome l\u00e4sst sich sonografisch eine RZA nachweisen.\n      Diese Patienten mit \u201estiller\u201c RZA ben\u00f6tigen dieselbe Therapie wie andere RZA-Patienten.\n      Zunehmend wird von einer RZA-PMR-Spektrum-Erkrankung ausgegangen.<\/jats:p><jats:p>\n            Therapie Glukokortikoide sind weiterhin die Haupts\u00e4ule in der\n      Therapie. Der Interleukin-6-Inhibitor Sarilumab wurde k\u00fcrzlich in den USA f\u00fcr rezidivierende\n      PMR zugelassen. Studien konnten auch eine Wirksamkeit von Tocilizumab zeigen.<\/jats:p>","DOI":"10.1055\/a-2144-8222","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T22:34:36Z","timestamp":1723761276000},"page":"1051-1055","source":"Crossref","is-referenced-by-count":2,"title":["Polymyalgia rheumatica \u2013 Was gibt es Neues?"],"prefix":"10.1055","volume":"149","author":[{"given":"Wolfgang A","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Rheumatologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin-Buch, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1055\/a-1074-7685.","article-title":"Inflammatory muscle pain: polymyalgia rheumatica with or without large vessel\n          vasculitis","volume":"145","author":"WA Schmidt","year":"2020","journal-title":"Dtsch Med Wochenschr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/rheumatology\/keac713.","article-title":"An international survey of current management practices for polymyalgia rheumatica\n          by general practitioners and rheumatologists","volume":"62","author":"AO Donskov","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"152260","DOI":"10.1016\/j.semarthrit.2023","article-title":"Early referral of patients with suspected polymyalgia rheumatica \u2013 A systematic\n          review","volume":"63","author":"AW Nielsen","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"ard-2023\u2013225134","DOI":"10.1136\/ard-2023-225134","article-title":"Recommendations for early referral of individuals with suspected polymyalgia\n          rheumatica: an initiative from the international giant cell arteritis and polymyalgia\n          rheumatica study group","author":"KK Keller","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"keae043","DOI":"10.1093\/rheumatology\/keae043","article-title":"Musculoskeletal magnetic resonance imaging findings support a common spectrum of\n          giant cell arteritis and polymyalgia rheumatica","author":"P Seitz","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/rheumatology\/keaa014","article-title":"Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance\n          imaging in polymyalgia rheumatica","volume":"59","author":"M Fruth","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"rkae003","DOI":"10.1093\/rap\/rkae003","article-title":"Characterising polymyalgia rheumatica on whole-body (18)F-FDG PET\/CT: an\n          atlas","volume":"8","author":"CE Owen","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00393-023-01413-7","article-title":"Diagnose der Polymyalgia rheumatica: Anamnese und Klinik kommen vor\n          Bildgebung","volume":"82","author":"W Hartung","year":"2023","journal-title":"Z Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","article-title":"Disease stratification in GCA and PMR: state of the art and future\n          perspectives","volume":"19","author":"A Tomelleri","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-024-01532-9","article-title":"Recommendations for defining giant cell arteritis fast-track clinics. English version","author":"WA Schmidt","year":"2024","journal-title":"Z Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"52069","DOI":"10.1016\/j.semarthrit.2022.152069","article-title":"Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica \u2013\n          A systematic review and meta-analysis","volume":"56","author":"AW Nielsen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kead189","article-title":"Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia\n          rheumatica","volume":"63","author":"E De Miguel","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221149963","article-title":"Prevalence and characteristics of giant cell arteritis in patients with newly\n            diagnosed polymyalgia rheumatica \u2013 a prospective cohort study","volume":"15","author":"LC Burg","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/ard-2023-224768","article-title":"Subclinical giant cell arteritis increases the risk of relapse in polymyalgia\n          rheumatica","volume":"83","author":"E De Miguel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","article-title":"S3-Leitlinie zur Behandlung der Polymyalgia rheumatica. Evidenzbasierte Leitlinie\n          der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh), der \u00d6sterreichischen Gesellschaft f\u00fcr\n          Rheumatologie und Rehabilitation (\u00d6GR) und der Schweizerischen Gesellschaft f\u00fcr\n          Rheumatologie (SGR) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften\n          und weiterer Organisationen","volume":"77","author":"F Buttgereit","year":"2018","journal-title":"Z Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): A phase\n          2\/3 randomised controlled trial","volume":"81","author":"M Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia\n          rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"V Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid\n          taper","volume":"389","author":"RF Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00393-024-01474-2","article-title":"Sarilumab bei Polymyalgia rheumatica","volume":"83","author":"WA Schmidt","year":"2024","journal-title":"Z Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the\n          efficacy and safety of sarilumab in patients with giant cell arteritis","volume":"25","author":"WA Schmidt","year":"2023","journal-title":"Arthritis Res Ther"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2144-8222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:17:39Z","timestamp":1730823459000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2144-8222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":20,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2144-8222","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}